GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia
2024/7/1
GEXVal Inc.July 1, 2024 GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia We are pleased to anno […]
GEXVal CEO Delivers Lecture at Kindai University*
2024/6/29
GEXVal Inc.June 29, 2024 GEXVal CEO Delivers Lecture at Kindai University* Juran Kato, PhD, President and CE […]
GEXVal Completes Additional Funding of JPY 110 Million in Series C Extension Round
2024/6/25
―To Accelerate Development in Australia and Expand the Pipeline― GEXVal Inc.June 25, 2024 GEXVal Completes A […]
GEXVal Sponsors SLTBR 2024 35th Annual Meeting
2024/6/18
GEXVal Inc.June 18, 2024 GEXVal Sponsors SLTBR 2024 35th Annual Meeting GEXVal Inc. is proud to sponsor the 35 […]
GEXVal CEO Delivers Guest Lecture at Keio University
2024/4/16
GEXVal Inc. April 16, 2024 Dr. Juran Kato, President and CEO of GEXVal Inc., presented at Keio University's Sh […]